Lifecore Biomedical LFCR Estimates

NASDAQ LFCR
$4.09 -0.22 (-5.10%)
As of: Sep 9, 2026 · 3:59 PM EDT
Analyst Estimates

Lifecore Biomedical, Inc. De Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 27.32 M

Analysts expect Lifecore Biomedical, Inc. De to report revenue of 27.32 M for Q3 26, against a range of 25.64 M to 28.99 M. The most recent reported quarter, Q2 26, came in at 34.17 M, a 1.7% beat against the 33.61 M consensus.

Metric Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 35.70 M37.89 M24.70 M32.56 M35.15 M36.44 M23.19 M34.17 M--------
High Estimate 38.88 M40.12 M25.61 M30.77 M36.97 M35.97 M27.88 M34.96 M28.99 M39.64 M29.75 M35.30 M29.30 M38.53 M34.58 M42.38 M
Low Estimate 36.53 M34.24 M23.98 M25.38 M32.80 M32.21 M22.87 M32.26 M25.64 M35.88 M25.64 M31.67 M26.16 M35.33 M29.26 M37.78 M
Consensus Estimate 37.71 M37.18 M24.80 M28.08 M34.88 M34.09 M25.38 M33.61 M27.32 M37.76 M27.69 M33.48 M27.73 M36.93 M31.92 M40.08 M
Analyst Estimates

Lifecore Biomedical, Inc. De Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus -0.32

Analysts expect Lifecore Biomedical, Inc. De to report earnings per share of -0.32 for Q3 26, against a range of -0.35 to -0.29. The most recent reported quarter, Q2 26, came in at -0.19, a 17.4% beat against the -0.23 consensus.

Metric Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 0.40-0.16-0.53-0.25-0.47-0.06-0.43-0.19--------
High Estimate -0.06-0.10-0.50-0.26-0.15-0.09-0.25-0.22-0.29-0.11-0.25-0.21-0.45-0.21-0.20-0.09
Low Estimate -0.06-0.12-0.54-0.28-0.17-0.09-0.29-0.24-0.35-0.11-0.29-0.23-0.49-0.23-0.24-0.09
Consensus Estimate -0.06-0.11-0.52-0.27-0.16-0.09-0.27-0.23-0.32-0.11-0.27-0.22-0.47-0.22-0.22-0.09